Company Profile · Basic Materials

Victrex plc

VCT · LSE
Industry
Specialty Chemicals
Exchange
LSE
Country
UK
Employees
1,169
Website
www.victrexplc.com
Current Price
7.65
Live · Jul 27, 2026
Fair Buy
≤ 4.8
Margin-of-safety entry
Baillie Growth Score
27/100
Poor
Intrinsic Value · Three-Tier Range Current price 7.65 Live · Between the fair and optimistic ranges

Composite valuation range · conservative 3–4.5 / fair 5.5–7.5 / optimistic 9–12. At 7.65, Between the fair and optimistic ranges.

At publication 6.29 (Jun 5, 2026)

Financial snapshot
Market cap£666.51M
Revenue (TTM)£293.9M
EBITDA£64.7M
Profit margin-6.7%
ROE-9.44%
Forward P/E15.55
PEG1.92
EPS-£0.00
Dividend yield7.97%
52-week range£5.04 – £7.67

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

About the company

Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; and sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, aerospace, automotive, and electronics markets, as well as engages in trading activities. It serves automotive, aerospace, energy and industrial, electronics, and medical markets. Victrex plc was incorporated in 1993 and is headquartered in Thornton-Cleveleys, the United Kingdom.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock
27/100 Watch Victrex (VCT.LSE) Zen Horizon Framework Deep Dive: The World's PEEK King Has Fallen 80%—A Great Asset Meets Structural Price Resets, a China Plant Write-Down, and a Dividend Cut Hanging Overhead The world's largest maker of PEEK (a high-performance engineering plastic), Victrex builds metal-replacement specialty polymers sold into aerospace, medical, electronics, and automotive; its leadership position, vertical integration, and Invibio implant-grade medical franchise (~75% gross margin) form a real moat. It is now hitting a structural pricing reset from low-cost Chinese PEEK (roughly half the import price)—volumes are rising but profits are falling, and underlying operating margin has been halved from 28% to 16.5%. Rating Watch: a world-class asset facing structural margin erosion and a likely dividend cut, cheap but not yet safe. Victrex plcVCT · LSESpecialty ChemicalsJun 5, 2026